Table 3.
Results of pathological fractures of both groups
| SBRT group | 3DCRT group | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | n/n (new) | % | 95% CI | N | n/n (new) | % | 95% CI | ||
| Pathological fracture | |||||||||
| All metastases | |||||||||
| Baseline (T0) | 27 | 11 | 40.7 | 0.224–0.621 | 28 | 5 | 17.9 | 0.061–0.369 | 0.062 |
| 3 months (T2) | 23 | 11/(2) | 47.8 | 0.268–0.694 | 23 | 5/(1) | 21.7 | 0.075–0.437 | 0.063 |
| 6 months (T3) | 18 | 11/(5) | 61.1 | 0.358–0.827 | 20 | 6/(1) | 30.0 | 0.119–0.543 | 0.054 |
| Subgroup analysis | |||||||||
| Osteolytic metastases | |||||||||
| Baseline (T0) | 8 | 2 | 25.0 | 0.032–0.651 | 4 | 0 | 0 | 0 | 0.273 |
| 3 months (T2) | 6 | 3/(2) | 50.0 | 0.118–0.882 | 4 | 1/(1) | 25.0 | 0.006–0.806 | 0.429 |
| 6 months (T3) | 6 | 3 | 50.0 | 0.118–0.882 | 3 | 1 | 33.3 | 0.008–0.906 | 0.635 |
| Osteoblastic metastases | |||||||||
| Baseline (T0) | 2 | 0 | 0 | 5 | 0 | 0 | |||
| 3 months (T2) | 2 | 0 | 0 | 4 | 0 | 0 | |||
| 6 months (T3) | 1 | 0 | 0 | 4 | 0 | 0 | |||
| Mixed metastases | |||||||||
| Baseline (T0) | 17 | 9 | 52.9 | 0.278–0.770 | 18 | 4 | 22.2 | 0.064–0.476 | 0.060 |
| 3 months (T2) | 15 | 8 | 53.33 | 0.266–0.787 | 14 | 3 | 21.4 | 0.047–0.508 | 0.077 |
| 6 months (T3) | 11 | 8/(5) | 72.7 | 0.390–0.940 | 12 | 4/(1) | 33.3 | 0.099–0.651 | 0.059 |
Abbreviations: N alive patients in group, n (new) number of new pathological fractures in the total number of pathological fractures, CI confidence interval